Any current/future new fundraising through debt or equity?

No explicit mention of any new fundraising through equity in the transcript. An increase in consolidated long-term borrowings was noted, primarily due to subsidiaries' working capital requirements, with tenures slightly over one year. Debt cost details were not fully disclosed; cost of debt was discussed but without specific new debt announcements. Capex guidance for FY2017 and FY2018 was Rs. 150 to 200 Crores, primarily funded internally for new API facilities and expansions. No direct statements about plans for raising fresh equity or debt beyond existing borrowings and capex plans.

Any current/future capex/capital investment/strategic investment?

Capex guidance for FY2017 and FY2018 is around Rs. 150 to 200 Crores, some of which may spill over to FY2018. Major capital expenditure is focused on the new API facility near Kolhapur, Maharashtra. Significant past capex incurred on the Goa plant, which is expected to be commissioned soon. Biosciences pilot plant also accounted for part of recent capital expenditure. Other expenditures mainly relate to maintenance and debottlenecking at existing plants. The Kolhapur API plant is still a few quarters away from starting operations and will require US FDA approval. Company plans to realign produ

Future growth expectations in sales/revenue/volumes?

US business expected to maintain robust growth with over 30% increase, supported by 16 pending approvals and new product launches. Domestic business aims for double-digit growth despite challenges from pricing regulations, focusing on volume increase and new product introductions across verticals. Domestic growth driven by improved per man productivity (above Rs. 2 lakhs) and expansion in cardiovascular and acute therapy clusters. Niche generics targeting breakeven soon with product launches in both US and tender markets to enhance traction and profitability. API plant at Kolhapur and

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects continued double-digit growth in topline driven by the US business and domestic formulation segments. US subsidiary experienced over 30% growth and targets maintaining this momentum with 6-8 ANDA filings this year. Domestic business aims to sustain high single-digit to low double-digit growth through volume increases and new products, despite challenges in pricing and market dynamics. Operating margins are expected to improve by 100 to 150 basis points driven by a better product mix and sales growth, although operating costs might not reduce significantly. Niche gen

Current/ Expected Orderbook/ Pending Orders?

The company has around 16 pending approvals in the US market. They have plans to file 2-3 ANDAs in Q1 FY17 and aim to maintain a filing rate of 1-2 filings every quarter, targeting 6-8 filings annually. Currently, 20 ANDAs are approved, with 14 products already launched, 2 expected launches in Q1, and a few more planned for Q2. The US subsidiary shows strong growth with focus on launching niche/high-value products and Para IV opportunities. New capacities, including a plant near Kolhapur and expansion at Goa, are expected to support upcoming filings and commercial launches. The growth strategy

Unichem LaboratoriesQ4 FY16Pharmaceuticals & Biotechnology

Unichem Laboratories Q4 FY16 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹498.75P/E: 29.5Market Cap: ₹3.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

US business expected to maintain robust growth with over 30% increase, supported by 16 pending approvals and new product launches.
Domestic business aims for double-digit growth despite challenges from pricing regulations, focusing on volume increase and new product introductions across verticals.
Domestic growth driven by improved per man productivity (above Rs. 2 lakhs) and expansion in cardiovascular and acute therapy clusters.
Niche generics targeting breakeven soon with product launches in both US and tender markets to enhance traction and profitability.
API plant at Kolhapur and biosciences pilot plant expansions expected to support future capacity and supply needs.
Increased ANDA filings planned—aiming for 6 to 8 filings annually to sustain product pipeline growth in regulated markets.
Overall, growth expected from a better product mix, expanding sales, and leveraging regulatory approvals in key international markets.

Margin guidance

Category 2

The company expects continued double-digit growth in topline driven by the US business and domestic formulation segments.
US subsidiary experienced over 30% growth and targets maintaining this momentum with 6-8 ANDA filings this year.
Domestic business aims to sustain high single-digit to low double-digit growth through volume increases and new products, despite challenges in pricing and market dynamics.
Operating margins are expected to improve by 100 to 150 basis points driven by a better product mix and sales growth, although operating costs might not reduce significantly.
Niche generics segment is close to breakeven and expected to turn profitable with capacity expansion and new product launches.
Consolidated breakeven after R&D expense is targeted from next year onwards, compared to partial R&D recovery currently.
Capital expenditure planned at Rs. 150-200 Crores mainly towards new API capacities, which will support future growth.
R&D spend remains steady at 4-5% of turnover, with potential increase if opportunities arise.

See what Unichem Laboratories management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any new fundraising through equity in the transcript.
An increase in consolidated long-term borrowings was noted, primarily due to subsidiaries' working capital requirements, with tenures slightly over one year.
Debt cost details were not fully disclosed; cost of debt was discussed but without specific new debt announcements.
Capex guidance for FY2017 and FY2018 was Rs. 150 to 200 Crores, primarily funded internally for new API facilities and expansions.
No direct statements about plans for raising fresh equity or debt beyond existing borrowings and capex plans.

Order book

The company has around 16 pending approvals in the US market.
They have plans to file 2-3 ANDAs in Q1 FY17 and aim to maintain a filing rate of 1-2 filings every quarter, targeting 6-8 filings annually.
Currently, 20 ANDAs are approved, with 14 products already launched, 2 expected launches in Q1, and a few more planned for Q2.
The US subsidiary shows strong growth with focus on launching niche/high-value products and Para IV opportunities.
New capacities, including a plant near Kolhapur and expansion at Goa, are expected to support upcoming filings and commercial launches.
The growth strategy is linked to the product approvals pipeline and capacity expansions, aiming to maintain and increase US business growth.

See what Unichem Laboratories management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex guidance for FY2017 and FY2018 is around Rs. 150 to 200 Crores, some of which may spill over to FY2018.
Major capital expenditure is focused on the new API facility near Kolhapur, Maharashtra.
Significant past capex incurred on the Goa plant, which is expected to be commissioned soon.
Biosciences pilot plant also accounted for part of recent capital expenditure.
Other expenditures mainly relate to maintenance and debottlenecking at existing plants.
The Kolhapur API plant is still a few quarters away from starting operations and will require US FDA approval.
Company plans to realign products between US FDA approved plants and the new facility to sustain US growth.
No aggressive increase planned in contract manufacturing business until new capacities come online.

Track Unichem Laboratories — get its next earnings analysis in your feed

How does Unichem Laboratories rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisUnichem Laboratories

Rev 3Mar 2

See where Unichem Laboratories sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Unichem Laboratories rank in Pharmaceuticals & Biotechnology?

Compare Unichem Laboratories against every Pharmaceuticals & Biotechnology company (Q4 FY16) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Unichem Laboratories's management said in earlier quarters

Earlier calls (3)

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules (Q2 FY27)
11.67% increase. Key results statement takeaways from Natural Capsules Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Sotac Pharmaceuticals (Q2 FY27)
7,654.95 lakhs; Operating margin ≈ 10.68% for HY Sep 2026 . Key results statement takeaways from Sotac Pharmaceuticals Ltd's Q2 FY27 results statement — and how
Bio Medica Lab (Q2 FY27)
EBITDA for the quarter:** ₹510 lakhs, up 25% year-on-year (YoY). Key results statement takeaways from Bio Medica Laboratories Ltd's Q2 FY27 results statement —
Syncom Formulations (India) (Q2 FY27)
Quarterly Revenue (Q2 FY 2026-27 ended 30/09/2026):** ₹14,821.08 lakhs (Unaudited) . Key results statement takeaways from Syncom Formulations (India) Ltd's Q2 F

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →